Canadian cannabis company Cronos Group Inc. CRON, -1.55% said Thursday it has agreed to acquire an 84,000 square foot fermentation and manufacturing facility in Winnipeg from Apotex Fermentation Inc. for an undisclosed sum. The facility will allow the company to produce cultured cannabinoids at commercial scale as part of its partership with Ginkgo Bioworks Inc., Toronto-based Cronos said in a statement. The deal is expected to close in the third quarter and will be paid for using cash on hand, which is not expected to be material to Cronos’s cash position. Shares rose 1.4% premarket, and have gained 47% in 2019, while the S&P 500 SPX, +0.45% has gained 19%.